Did Nixon Peabody and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo usher in the demise of a biotech startup that was poised to thwart cancer and potentially earn billions in the process?
That’s the premise of a 45-page complaint filed Tuesday in U.S. district court on Long Island by Neogenix Oncology Inc., a bankrupt developer of cancer diagnostic and treatment products. The suit claims that the two law firms stood idly by for years while Neogenix’s chief financial officer blatantly violated securities laws, leading to an investigation by the U.S. Securities and Exchange Commission and financial ruin.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
